Prothena Corp. (NASDAQ:PRTA) saw an uptick in trading volume on Wednesday . 328,962 shares changed hands during trading, a decline of 0% from the previous session’s volume of 330,150 shares.The stock last traded at $54.98 and had previously closed at $54.19.

Several research firms have recently weighed in on PRTA. Credit Suisse Group AG reaffirmed a “buy” rating on shares of Prothena Corp. in a report on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and set a $77.00 target price on shares of Prothena Corp. in a report on Wednesday, August 3rd. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corp. in a report on Friday, June 10th. Barclays PLC began coverage on shares of Prothena Corp. in a report on Friday, May 13th. They set an “overweight” rating and a $60.00 target price for the company. Finally, Zacks Investment Research raised shares of Prothena Corp. from a “sell” rating to a “hold” rating in a report on Friday, May 6th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $76.60.

The company’s market capitalization is $1.73 billion. The company has a 50 day moving average of $52.82 and a 200 day moving average of $43.75.

Prothena Corp. (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, August 2nd. The company reported ($1.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.91) by $0.27. The business had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.39 million. The business’s revenue for the quarter was up 22.2% compared to the same quarter last year. On average, equities research analysts expect that Prothena Corp. will post ($4.25) earnings per share for the current year.

In other news, insider Arthur W. Homan sold 9,375 shares of the stock in a transaction that occurred on Wednesday, July 20th. The stock was sold at an average price of $52.14, for a total value of $488,812.50. Following the completion of the sale, the insider now directly owns 9,375 shares of the company’s stock, valued at $488,812.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Several large investors have recently bought and sold shares of the stock. New York State Common Retirement Fund increased its stake in Prothena Corp. by 4.0% in the fourth quarter. New York State Common Retirement Fund now owns 31,000 shares of the company’s stock valued at $2,111,000 after buying an additional 1,200 shares during the last quarter. Wells Fargo & Company MN increased its stake in Prothena Corp. by 2,138.8% in the fourth quarter. Wells Fargo & Company MN now owns 245,639 shares of the company’s stock valued at $16,730,000 after buying an additional 234,667 shares during the last quarter. Finally, Jennison Associates LLC increased its stake in Prothena Corp. by 0.5% in the fourth quarter. Jennison Associates LLC now owns 406,677 shares of the company’s stock valued at $27,699,000 after buying an additional 1,912 shares during the last quarter.

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.